107 related articles for article (PubMed ID: 23243270)
1. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.
McCormack E; Mujić M; Osdal T; Bruserud Ø; Gjertsen BT
Blood; 2013 Feb; 121(7):e34-42. PubMed ID: 23243270
[TBL] [Abstract][Full Text] [Related]
2. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
Fredly H; Reikvam H; Gjertsen BT; Bruserud O
Am J Hematol; 2012 Apr; 87(4):368-76. PubMed ID: 22374841
[TBL] [Abstract][Full Text] [Related]
3. [Expanding possibilities, strategic considerations, and novel methods in the diagnosis and chemotherapy of adult acute myeloid leukemia].
Udvardy M
Orv Hetil; 2003 Sep; 144(36):1769-77. PubMed ID: 14579674
[TBL] [Abstract][Full Text] [Related]
4. In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization.
McCormack E; Micklem DR; Pindard LE; Silden E; Gallant P; Belenkov A; Lorens JB; Gjertsen BT
Mol Imaging; 2007; 6(3):193-204. PubMed ID: 17532885
[TBL] [Abstract][Full Text] [Related]
5. New synergistic combinations of differentiation-inducing agents in the treatment of acute promyelocytic leukemia cells.
Amanzadeh A; Molla-Kazemiha V; Samani S; Habibi-Anbouhi M; Azadmanesh K; Abolhassani M; Shokrgozar MA
Leuk Res; 2018 May; 68():98-104. PubMed ID: 29602066
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.
Leitch C; Osdal T; Andresen V; Molland M; Kristiansen S; Nguyen XN; Bruserud Ø; Gjertsen BT; McCormack E
Oncotarget; 2016 Feb; 7(7):8105-18. PubMed ID: 26812881
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
Ying M; Zhou X; Zhong L; Lin N; Jing H; Luo P; Yang X; Song H; Yang B; He Q
Mol Cancer Ther; 2013 Feb; 12(2):195-206. PubMed ID: 23243061
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
9. Ethyl acetate extract of Caesalpinia sappan L. inhibited acute myeloid leukemia via ROS-mediated apoptosis and differentiation.
Ma HY; Wang CQ; He H; Yu ZY; Tong Y; Liu G; Yang YQ; Li L; Pang L; Qi HY
Phytomedicine; 2020 Mar; 68():153142. PubMed ID: 32045840
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
Raffoux E; Chaibi P; Dombret H; Degos L
Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941
[TBL] [Abstract][Full Text] [Related]
11. Optical imaging of disseminated leukemia models in mice with near-infrared probe conjugated to a monoclonal antibody.
Pesnel S; Pillon A; Créancier L; Lerondel S; Le Pape A; Recher C; Demur C; Guilbaud N; Kruczynski A
PLoS One; 2012; 7(1):e30690. PubMed ID: 22303450
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.
Imaizumi M; Tawa A; Hanada R; Tsuchida M; Tabuchi K; Kigasawa H; Kobayashi R; Morimoto A; Nakayama H; Hamamoto K; Kudo K; Yabe H; Horibe K; Tsuchiya S; Tsukimoto I
Br J Haematol; 2011 Jan; 152(1):89-98. PubMed ID: 20735397
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
Clin Cancer Res; 2016 Mar; 22(5):1211-21. PubMed ID: 26459180
[TBL] [Abstract][Full Text] [Related]
14. CD7 false-positive acute myelogenous leukemia and promyelocytic leukemia cell line HL-60: characterization of CD7 epitopes by four monoclonal antibodies.
Imamura N; Ota H; Kuramoto A
Am J Hematol; 1991 Sep; 38(1):72-4. PubMed ID: 1716852
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
[TBL] [Abstract][Full Text] [Related]
16. Stepwise discriminant function analysis for rapid identification of acute promyelocytic leukemia from acute myeloid leukemia with multiparameter flow cytometry.
Chen Z; Li Y; Tong Y; Gao Q; Mao X; Zhang W; Xia Z; Fu C
Int J Hematol; 2016 Mar; 103(3):306-15. PubMed ID: 26759321
[TBL] [Abstract][Full Text] [Related]
17. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
Grishina O; Schmoor C; Döhner K; Hackanson B; Lubrich B; May AM; Cieslik C; Müller MJ; Lübbert M
BMC Cancer; 2015 May; 15():430. PubMed ID: 26008690
[TBL] [Abstract][Full Text] [Related]
18. [Combination chemotherapy for acute myeloid leukemia].
Nagai T
Nihon Rinsho; 2009 Oct; 67(10):1921-5. PubMed ID: 19860191
[TBL] [Abstract][Full Text] [Related]
19. Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.
Grønningsæter IS; Fredly HK; Gjertsen BT; Hatfield KJ; Bruserud Ø
Cells; 2019 Oct; 8(10):. PubMed ID: 31658693
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
